Peter Maag, PhD, CEO of Kyverna Therapeutics, recalls when people said biologics such as monoclonal antibodies would never work for mass-market applications. “People said that [biologics] are too ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback